Enveric Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Enveric Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than almost all Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 666% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than almost all Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Enveric Biosciences, Inc. made a loss over the last year. Enveric Biosciences, Inc. owes $0.10 for every $1 it owns. Enveric Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossEnveric Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.81The share price is 0.81 times Enveric Biosciences, Inc.'s book value per share, lower than 84% of Healthcare companies in United States.
Market cap
$7 MThe total market value of all of Enveric Biosciences, Inc.'s shares at today's price (share price × number of shares), smaller than 91% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$8 MWhat Enveric Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.81Net worth divided by the number of shares. The share price of $1.46 is 0.8 times this, which is the P/B above.
Return on equity (ROE)
-170.0%Enveric Biosciences, Inc. lost 170.0% of its shareholders' money over the last year, lower than 82% of Healthcare companies in United States.
Owes vs Owns
0.10×Enveric Biosciences, Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Dividend yield
NoneEnveric Biosciences, Inc. does not currently pay a dividend.
Profit growth
LossEnveric Biosciences, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Enveric Biosciences, Inc.: $7 M ÷ $8 M (30 Jun 2026) = 0.8.
What is Enveric Biosciences, Inc.'s return on equity?
Enveric Biosciences, Inc. lost 170.0% of its shareholders' money over the last year, lower than 82% of Healthcare companies in United States.
How much does Enveric Biosciences, Inc. owe compared with what it owns?
Enveric Biosciences, Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Does Enveric Biosciences, Inc. pay a dividend?
No. Enveric Biosciences, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.